Gikakis Nicolas
Known title: DirectorCIK: 0001982603
Associated companies
Transaction History
| AEMD | ▼ Sell | Tax Withholding | 2,182 | $2K | 6/30/2026 | View on chart |
| AEMD | ▲ Buy | Grant | 21,815 | $50K | 4/17/2026 | View on chart |
| AEMD | ▼ Sell | Tax Withholding | 178 | $390 | 3/31/2026 | View on chart |
| AEMD | ▼ Sell | Tax Withholding | 179 | $496 | 12/31/2025 | View on chart |
| AEMD | ▼ Sell | Tax Withholding | 1,786 | $1K | 9/30/2025 | View on chart |
| AEMD | ▼ Sell | Tax Withholding | 1,786 | $2K | 6/30/2025 | View on chart |
| AEMD | ▲ Buy | Grant | 142,857 | $50K | 4/23/2025 | View on chart |
| AEMD | ▼ Sell | Tax Withholding | 3,289 | $1K | 3/31/2025 | View on chart |
| AEMD | ▼ Sell | Tax Withholding | 3,289 | $3K | 12/31/2024 | View on chart |
| AEMD | ▼ Sell | Tax Withholding | 3,289 | $2K | 9/30/2024 | View on chart |
| AEMD | ▼ Sell | Tax Withholding | 5,244 | $3K | 6/28/2024 | View on chart |
| AEMD | ▲ Buy | Grant | 32,894 | $50K | 4/16/2024 | View on chart |
| AEMD | ▼ Sell | Tax Withholding | 1,954 | $3K | 3/29/2024 | View on chart |
| AEMD | ▼ Sell | Tax Withholding | 1,954 | $4K | 12/29/2023 | View on chart |
| AEMD | ▼ Sell | Tax Withholding | 19,541 | $4K | 9/29/2023 | View on chart |
| AEMD | ▲ Buy | Grant | 195,414 | $0 | 7/3/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
AEMD Holds Shareholder/Analyst Call, Transcript Released
Aethlon Medical Inc. released a transcript of its recent shareholder and analyst call. The prepared remarks provided management’s update on company developments and outlook. The release gives investors additional information to assess the business amid the stock’s elevated RSI reading.
AEMD Holds Shareholder/Analyst Call, Transcript Released. Aethlon Medical Inc. released a transcript of its recent shareholder and analyst call. The prepared remarks provided management’s update on company developments and outlook. The release gives investors additional information to assess the business amid the stock’s elevated RSI reading.